Desmoglein 2 and Kallikrein 7 in Pancreatic Cancer
Author Information
Author(s): Ramani Vishnu C, Hennings Leah, Haun Randy S
Primary Institution: University of Arkansas for Medical Sciences
Hypothesis
Does kallikrein 7 degrade desmogleins in pancreatic cancer cells?
Conclusion
The study found that desmogleins 1 and 2 are reduced in pancreatic cancer, and kallikrein 7 can degrade these proteins, potentially aiding cancer invasion.
Supporting Evidence
- Desmogleins 1 and 2 showed reduced levels in pancreatic adenocarcinomas compared to normal tissues.
- Kallikrein 7 was found to cleave both Dsg1 and Dsg2 in vitro.
- Overexpression of kallikrein 7 in BxPC-3 cells led to increased shedding of soluble Dsg2.
Takeaway
In pancreatic cancer, important proteins that help cells stick together are broken down by a specific enzyme, which might help the cancer spread.
Methodology
The study used immunohistochemistry and western blot analysis to assess desmoglein expression and degradation assays to test the effect of kallikrein 7.
Potential Biases
Potential bias in the selection of tissue samples and cell lines used for analysis.
Limitations
The study primarily focused on two pancreatic cancer cell lines and may not represent all pancreatic cancer types.
Participant Demographics
Human pancreatic tissues from non-malignant, chronic pancreatitis, and pancreatic adenocarcinoma samples.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website